Influenza virus vaccination of patients with multiple sclerosis.
Prior to vaccination with a trivalent influenza vaccine (AT/Texas, AB/Beijing, and BP/Panama), sera from 19 MS patients had a significantly higher mean level of antibody than 9 normal subjects to AT strain of influenza, but not to AB or BP strains. After Flu vaccination, the mean anti-AT and anti-AB antibody titers significantly increased 4-fold in 11 MS patients and 9 normal subjects. The ratio of MS responders (6/11), however, was lower than normal (8/9). The mean PBL proliferative response to the Flu antigens increased after vaccination significantly more in MS patients than in normal subjects, and increased in 9 of 11 MS patients and 3 of 9 normal subjects. Although MS patients responded to Flu antigens with higher antibody levels and proliferative responses of PBL, than normal subjects, a clinical protective effect of the vaccine against Flu was not clearly demonstrated in these patients, and vaccination did not cause or protect against exacerbation of MS.
Mokhtarian
F
F
Department of Medicine, SUNY Health Science Center/Maimonides Medical Center, Brooklyn 11219, USA.
Shirazian
D
D
Morgante
L
L
Miller
A
A
Grob
D
D
Lichstein
E
E
D000328:Adult; D000914:Antibodies, Viral / Q000097:blood*; D000917:Antibody Formation; D005260:Female; D006801:Humans; D009980:Influenza A virus / Q000145:classification / Q000276:immunology*; D007252:Influenza Vaccines; D007251:Influenza, Human / Q000276:immunology* / Q000517:prevention & control; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000276:immunology*; D012016:Reference Values
D000914:Antibodies, Viral; D007252:Influenza Vaccines